We here demonstrated that erlotinib induces an accumulation of EGFR and/or HER2 protein at the plasma membrane level only in TKI sensitive NSCLC cell lines whereas, in resistant cells (both, intrinsic or MET amplification-mediated acquired resistance), this enhancement was not observed. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.